Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs

• Isabella Monia Montagner,

  Affiliation Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

  ⨯
• Anna Merlo,

  Affiliation Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

  ⨯
• Gaia Zuccolotto,

  Affiliation Department of Medicine, University of Padua, Padua, Italy

  ⨯
• Davide Renier,

  Affiliation Fidia Farmaceutici S.p.A., Abano Terme, Italy

  ⨯
• Monica Campisi,

  Affiliation Fidia Farmaceutici S.p.A., Abano Terme, Italy

  ⨯
• Gianfranco Pasut,

  Affiliation Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

  ⨯
• Paola Zanovello,

  Affiliations Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

  ⨯
• Antonio Rosato

  * E-mail: antonio.rosato@unipd.it

  Affiliations Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

  ⨯